4584.T
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biopharmaceutical products.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biopharmaceutical products.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biopharmaceutical products.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥2,995,435,000, which significantly exceeds its total liabilities of ¥5,597,519,000, as reflected in the current ratio of 1.55. The price-to-book ratio of 5.84 indicates that the market is valuing the company's equity at a premium relative to its book value. However, the company's return on equity of -0.015 and return on assets of -0.003 suggest that it is not generating positive returns for its shareholders or asset base.
The company's profitability is underperforming, with a net loss of ¥21,141,000 and an operating income of only ¥29,232,000, which is significantly below the industry median for biotechnology firms. The gross profit margin of 32.27% is also below the industry average, indicating that the company is facing challenges in maintaining its gross margins.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which could expose it to regional economic or regulatory risks. The company's capital structure is characterized by a high debt-to-equity ratio of 1.3, indicating a significant reliance on debt financing.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year and no clear guidance for the next fiscal year. The company's free cash flow is negative at -¥26,685,000, which could limit its ability to invest in growth opportunities or return value to shareholders.
The company's risk assessment indicates a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure and financial performance suggest that it is not currently facing significant dilution pressures, and the number of shares outstanding has not changed between basic and diluted shares.
Recent events and filings do not indicate any significant changes in the company's financial or operational performance. The company's price target from analysts is ¥450.00, with a mean recommendation of 2.00, indicating a generally positive outlook from the analyst community.
- The company has a strong liquidity position with a current ratio of 1.55 and significant cash reserves.
- The company is not generating positive returns for its shareholders, with a negative return on equity and return on assets.
- The company's profitability is underperforming, with a net loss and low operating income.
- The company's revenue is concentrated in a single business segment, which could expose it to regional economic or regulatory risks.
- The company's growth trajectory is uncertain, with no clear guidance for the next fiscal year.
- "margin_outlook_rationale": "The company's gross profit margin is below the industry average, indicating potential challenges in maintaining margins.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 10,30 |
| Revenue | —no estimate | —no estimate | 4,3B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 4584.T Market data — financials · 2026-05-26
- Kidswell Bio Corp Market data — analyst estimates · 2026-05-26